Moving forward in carcinogenicity assessment: Report of an EURL ECVAM/ESTIV workshop

Toxicology in Vitro

Volumn 45, Issue , 2017, Pages 278-286

  Corvi, Raffaella ^a   Madia, Federica ^a   Guyton, Kathryn Z ^b   Kasper, Peter ^c   Rudel, Ruthann ^d   Colacci, Annamaria ^e   Kleinjans, Jos ^f   Jennings, Paul ^g  

^a JOINT RESEARCH CENTRE   (Italy)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c Federal Institute for Drugs and Medical Devices BfArM   (Germany)

^d SILENT SPRING INSTITUTE   (United States)

^e Center for Environmental Carcinogenesis and Risk Assessment   (Italy)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g AMSTERDAM INSTITUTE FOR MOLECULES   (Netherlands)

Author keywords

Alternative methods; Cancer hallmarks; Carcinogenicity; CTA; Mechanisms; Rodent bioassay; Toxicogenomics

Indexed keywords

ANIMAL TESTING ALTERNATIVE; BIOASSAY; BREAST CARCINOGENESIS; CARCINOGEN TESTING; CELL ASSAY; CELL TRANSFORMATION ASSAY; CONFERENCE PAPER; DRUG LEGISLATION; EUROPEAN UNION; GENOTOXICITY; HAZARD ASSESSMENT; HUMAN; INFORMATION PROCESSING; NONHUMAN; RODENT; STRATEGIC PLANNING; VETERINARY MEDICINE; ANIMAL; BREAST TUMOR; CHEMICALLY INDUCED; CONSENSUS DEVELOPMENT; EUROPE; FEMALE; MOUSE; PROPORTIONAL HAZARDS MODEL; RAT; TECHNOLOGY; TOXICOGENETICS; TRENDS;

CARCINOGEN;

ANIMAL TESTING ALTERNATIVES; ANIMALS; BREAST NEOPLASMS; CARCINOGENICITY TESTS; CARCINOGENS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; EUROPE; FEMALE; HUMANS; MICE; PROPORTIONAL HAZARDS MODELS; RATS; TECHNOLOGY; TOXICOGENETICS;

EID: 85030635655     PISSN: 08872333     EISSN: 18793177     Source Type: Journal    
DOI: 10.1016/j.tiv.2017.09.010     Document Type: Conference Paper

References (70)

1. Adler, S., Basketter, D., Creton, S., Pelkonen, O., van Benthem, J., Zuang, V., Zaldivar, J.M., Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010. Arch. Toxicol. 85:5 (2011), 367–485, 10.1007/s00204-011-0693-2.
2. Annys, E., Billington, R., Clayton, R., Bremm, K.-D., Graziano, M., Mckelvie, J., Woodward, K.N., Advancing the 3Rs in regulatory toxicology †Carcinogenicity testing: scope for harmonisation and advancing the 3Rs in regulated sectors of the European Union. Regul. Toxicol. Pharmacol. 69 (2014), 234–242, 10.1016/j.yrtph.2014.04.009.
3. Aschauer, L., Gruber, L.N., Pfaller, W., Limonciel, A., Athersuch, T.J., Cavill, R., Jennings, P., Delineation of the key aspects in the regulation of epithelial monolayer formation. Mol. Cell. Biol. 33:13 (2013), 2535–2550, 10.1128/MCB.01435-12.
4. Aschauer, L., Limonciel, A., Wilmes, A., Stanzel, S., Kopp-Schneider, A., Lukas, H.P., Lukas, A., Leonard, M.O., Pfaller, W., P., J., Application of RPTEC/TERT1 cells for investigation of repeat dose nephrotoxicity: a transcriptomic study. Toxicol. in Vitro 30:1 Pt A (2015), 106–116, 10.1016/j.tiv.2014.10.005.
5. TM high-throughput data. Environ. Health Perspect. 124:8 (2016), 1141–1154, 10.1289/ehp.1510456.
6. Billinton, N., Bruce, S., Hansen, J.R., Hastwell, P.W., Jagger, C., McComb, C., Walmsley, R.M., A pre-validation transferability study of the GreenScreen HC GADD45a-GFP assay with a metabolic activation system (S9). Mutat. Res. 700:1–2 (2010), 44–50, 10.1016/j.mrgentox.2010.05.001.
7. Birnbaum, L.S., Fenton, S., Cancer and developmental exposure to endocrine disruptors. Environ. Health Perspect. 111:4 (2003), 389–394.
8. Boei, J.J., Vermeulen, S., Klein, B., Hiemstra, P.S., Verhoosel, R.M., Jennen, D.G., Lahoz, A., Gmuender, H., H., V., Xenobiotic, Xenobiotic metabolism in differentiated human bronchial epithelial cells. Arch. Toxicol.(October 13), 2016, 10.1007/s00204-016-1868-7.
9. van Breda, S.G.J., Claessen, S.M.H., Lo, K., van Herwijnen, M., Brauers, K.J.J., Lisanti, S., Kleinjans, J.C.S., Epigenetic mechanisms underlying arsenic-associated lung carcinogenesis. Arch. Toxicol. 89:11 (2015), 1959–1969 http://doi.org/10.1007/s00204-014-1351-2.
10. Brody, J.G., Rudel, R., Environmental pollutants and breast cancer: the evidence from animal and human studies. Breast Dis. 19:1 (2008), 17–19.
11. Contrera, J.F., Jacobs, A.C., DeGeorge, J.J., Carcinogenicity testing and the evaluation of regulatory requirements for pharmaceuticals. Regul. Toxicol. Pharmacol. 25:2 (1997), 130–145, 10.1006/rtph.1997.1085.
12. Creton, S., Aardema, M.J., Carmichael, P.L., Harvey, J.S., Martin, F.L., Newbold, R.F., Yasaei, H., Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs. Mutagenesis 27:1 (2012), 93–101, 10.1093/mutage/ger053.
13. Daneshian, M., Busquet, F., Hartung, T., Leist, M., Animal use for science in Europe. ALTEX 32:4 (2015), 261–274, 10.14573/altex.1509081.
14. DG ENV Report, Seventh Report from the Commission to the Council and the European Parliament on the Statistics on the Number of Animals Used for Experimental and Other Scientific Purposes in the Member States of the European Union COM(2013)859/Final. Vol. 859, 2013.
15. Doktorova, T.Y., Yildirimman, R., Vinken, M., Vilardell, M., Vanhaecke, T., Gmuender, H., Rogiers, V., Transcriptomic responses generated by hepatocarcinogens in a battery of liver-based in vitro models. Carcinogenesis 34:6 (2013), 1393–1402, 10.1093/carcin/bgt054.
16. Doktorova, T.Y., Yildirimman, R., Ceelen, L., Vilardell, M., Vanhaecke, T., Vinken, M., Rogiers, V., Testing chemical carcinogenicity by using a transcriptomics heparg-based model?. EXCLI J. 13 (2014), 623–637.
17. EC Regulation 1107, Regulation (EC) No 1107/2009 of the european parliament and of the council of 21 october 2009 concerning the placing of plant protection products on the market and repealing Council Directives 79/117/EEC and 91/414/EEC. Off. J. Eur. Union 309:24/11/2009 (2009), 1–50.
18. EC Regulation 1223, Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. Off. J. Eur. Union 342:52 (2009), 59–209.
19. EC Regulation 1272, Regulation (EC) No. 1272/2008 of the European Parliament and of the council on classification, labelling and packaging of substances and mixtures, amending and repealing directives 67/548/EEC and 1999/45/EC, and amending regulation (EC) no 1907/2006. Off. J. Eur. Union 353:16.12.2008 (2008), 1–1355.
20. EC Regulation 1907., Regulation (ec) no 1907/2006 of the european parliament and of the COUNCIL of 18 December 2006 concerning the registration, evaluation, authorisation and restriction of chemicals (REACH), establishing a European chemicals agency, amending directive 1999/4. Off. J. Eur. Union 396:793 (2006), 1–849 http://doi.org/http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:396:0001:0849:EN:PDF.
21. EU Regulation 283, Regulation (EU) No 283/2013 setting out the data requirements for active substances, in accordance with Regulation (EC) No 1107/2009 of the European Parliament and of the Council concerning the placing of plant protection products on the market. Off. J. Eur. Union 93:3 (2013), 1–84 of 01.03.2013.
22. EU Regulation 528, Regulation (EU) no 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products. Off. J. Eur. Union 167 (2012), 1–123.
23. Friedrich, A., Olejniczak, K., Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995-2009). Regul. Toxicol. Pharmacol. 60:2 (2011), 225–248, 10.1016/j.yrtph.2011.04.001.
24. Goodson, W.H., Lowe, L., Carpenter, D.O., Gilbertson, M., Ali, A.M., de Cerain Salsamendi, A.L., Hu, Z., Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis 36 (2015), S254–S296, 10.1093/carcin/bgv039.
25. Grosse, Y., Loomis, D., Guyton, K.Z., El Ghissassi, F., Bouvard, V., Benbrahim-Tallaa, L., Straif, K., Carcinogenicity of some industrial chemicals. Lancet Oncol. 17:4 (2016), 419–420, 10.1016/S1470-2045(16)00137-6.
26. Guyton, K.Z., Kyle, A.D., Aubrecht, J., Cogliano, V.J., Eastmond, D.A., Jackson, M., Smith, M.T., Improving prediction of chemical carcinogenicity by considering multiple mechanisms and applying toxicogenomic approaches. Mutat. Res. Rev. Mutat. Res. 681:2–3 (2009), 230–240, 10.1016/j.mrrev.2008.10.001.
27. Guyton, K.Z., Loomis, D., Grosse, Y., El Ghissassi, F., Benbrahim-Tallaa, L., Guha, N., Zeise, L., Carcinogenicity of tetrachlorvinphos, parathion, malathion, diazinon, and glyphosate. Lancet Oncol. 16:5 (2015), 490–491, 10.1016/S1470-2045(15)70134-8.
28. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell, 2011, 10.1016/j.cell.2011.02.013.
29. Hendriks, G., Derr, R.S., Misovic, B., Morolli, B., Call??ja, F. M. G. R., & Vrieling, H., The extended ToxTracker assay discriminates between induction of DNA damage, oxidative stress, and protein misfolding. Toxicol. Sci. 150:1 (2016), 190–203, 10.1093/toxsci/kfv323.
30. Herwig, R., Gmuender, H., Corvi, R., Bloch, K.M., Brandenburg, A., Castell, J., Kleinjans, J., Inter-laboratory study of human in vitro toxicogenomics-based tests as alternative methods for evaluating chemical carcinogenicity: a bioinformatics perspective. Arch. Toxicol. 90:9 (2016), 2215–2229, 10.1007/s00204-015-1617-3.
31. IARC, A review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum., 100A, 2012.
32. IBCERCC, Breast Cancer and the Environment: Prioritizing Prevention. 2013.
33. ICH, Regulatory notice document. Proposed Change to Rodent Carcinogenicity Testing of Pharmaceuticals, 2016.
34. ICH S1, S1 rodent carcinogenicity studies for human pharmaceuticals. Guidance for Industry, 2012 September 2013.
35. ICH S1A., S1A Guideline on the need for carcinogenecity studies. Guidance for Industry, Step 4:March (1996), 1–8.
36. ICH S1B, S1B Guidance on testing for carcinogenicity of pharmaceuticals. Guidance for Industry, Step 5:July (1997), 1–11.
37. ICH Status Report, The ICHS1 regulatory testing paradigm of carcinogenicity in rats - status report. Safety Guidelines 2:March (2016), 1–5.
38. International Agency for Research on Cancer, IARC monographs on the evaluation of carcinogenic risks to humans. Dis. Colon Rectum, 49(6), 2006, 791, 10.1007/s10350-006-0552-z.
39. International Agency for Research on Cancer, IARC monographs volume 112: evaluation of five organophosphate insecticides and herbicides. Environ. Health 112 (2017), 1–464.
40. IOM, Breast Cancer and the Environment: A Life Course Approach. 2011, National Academies, Washington DC.
41. Jacobs, A.C., Brown, P.C., Regulatory Forum Opinion Piece*. Transgenic/Alternative Carcinogenicity Assays: A Retrospective Review of Studies Submitted to CDER/FDA 1997–2014 50:2 (2013), 324–333 http://doi.org/10.1177/0192623314566241.
42. Jacobs, M.N., Colacci, A., Louekari, K., Luijten, M., Hakkert, B.C., Paparella, M., P., V., International regulatory needs for development of an IATA for non-genotoxic carcinogenic chemical substances. ALTEX, 2016 April 27 10.14573/altex.1601201.
43. Kavlock, R., Chandler, K., Houck, K., Hunter, S., Judson, R., Kleinstreuer, N., Dix, D., Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. Chem. Res. Toxicol., 2012, 10.1021/tx3000939.
44. Kirkland, D., Aardema, M., Henderson, L., Müller, L., Evaluation of the ability of a battery of three in vitro genotoxicity tests to discriminate rodent carcinogens and non-carcinogens. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 584:1–2 (2005), 1–256 http://doi.org/10.1016/j.mrgentox.2005.02.004.
45. Knight, A., Bailey, J., Balcombe, J., Animal carcinogenicity studies: 1. Poor human predictivity. Alternatives to Laboratory Animals : ATLA 34:1 (2006), 19–27.
46. van der Laan, J.W., Kasper, P., Silva Lima, B., Jones, D.R., Pasanen, R., Critical analysis of carcinogenicity study outcomes. Relationship with pharmacological properties. Crit. Rev. Toxicol. 26 (2016), 1–28.
47. Loomis, D., Guyton, K., Grosse, Y., El Ghissasi, F., Bouvard, V., Benbrahim-Tallaa, L., Straif, K., Carcinogenicity of lindane, DDT, and 2,4-dichlorophenoxyacetic acid. Lancet Oncol., 2015 http://doi.org/10.1016/S1470-2045(15)00081-9.
48. Madia, F., Worth, A., Corvi, R., Analysis of carcinogenicity testing for regulatory purposes in the European Union. European Commission, EUR, 27765, 2016 http://doi.org/10.2788/547846.
49. Magkoufopoulou, C., Claessen, S.M.H., Tsamou, M., Jennen, D.G.J., Kleinjans, J.C.S., Van delft, J. H. M., A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis 33:7 (2012), 1421–1429 http://doi.org/10.1093/carcin/bgs182.
50. Ormandy, E.H., Dale, J., Griffin, G., Genetic engineering of animals: ethical issues, including welfare concerns. Can. Vet. J. 52:5 (2011), 544–550.
51. Paparella, M., Uncertainties of testing methods: What do we (want to) know about carcinogenicity?. ALTEX, 2016 Oct 24 10.14573/altex.1608281.
52. Paules, R.S., Aubrecht, J., Corvi, R., Garthoff, B., Kleinjans, J.C., Moving forward in human cancer risk assessment. Environ. Health Perspect. 119:6 (2011), 739–743 http://doi.org/10.1289/ehp.1002735.
53. Rieswijk, L., Brauers, K.J.J., Coonen, M.L.J., Jennen, D.G.J., Van Breda, S.G.J., Kleinjans, J.C.S., Exploiting microRNA and mRNA profiles generated in vitro from carcinogen-exposed primary mouse hepatocytes for predicting in vivo genotoxicity and carcinogenicity. Mutagenesis 31:5 (2016), 603–615 http://doi.org/10.1093/mutage/gew027.
54. Rieswijk, L., Claessen, S.M., Bekers, O., van Herwijnen, M., Theunissen, D.H., J. D., & de Kok TM, Kleinjans JC, van B. S., Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology 350–352 (2016), 31–39 http://doi.org/10.1016/j.tox.2016.05.002.
55. Rudel, R.A., Attfield, K.R., Schifano, J.N., Brody, J.G., Chemicals causing mammary gland tumors in animals signal new directions for epidemiology, chemicals testing, and risk assessment for breast cancer prevention. Cancer, 2007, 10.1002/cncr.22653.
56. Rudel, R.A., Fenton, S.E., Ackerman, J.M., Euling, S.Y., Makris, S.L., Environmental exposures and mammary gland development: state of the science, public health implications, and research recommendations. Environ. Health Perspect., 119(8), 2011.
57. Rudel, R.A., Ackerman, J.M., Attfield, K.R., Brody, J.G., New exposure biomarkers as tools for breast cancer epidemiology, biomonitoring, and prevention: a systematic approach based on animal evidence. Environ. Health Perspect., 2014, 10.1289/ehp.1307455.
58. SCCS, Notes of Guidance for the Testing of Cosmetics Substances and their Safety Evaluation, 9th Revision, SCCS/1564/. 2015.
59. Schwarzman, M.R., Ackerman, J.M., Dairkee, S.H., Fenton, S.E., Johnson, D., N. K., & Osborne G, Rudel RA, Solomon GM, Zeise L, J. S., Screening for chemical contributions to breast cancer risk: a case study for chemical safety evaluation. Environ. Health Perspect. 123:12 (2015), 1255–1264 http://doi.org/10.1289/ehp.1408337.
60. Sistare, F.D., Morton, D., Alden, C., Christensen, J., Keller, D., Jonghe, S. De, DeGeorge, J.J., An analysis of pharmaceutical experience with decades of rat carcinogenicity testing: support for a proposal to modify current regulatory guidelines. Toxicol. Pathol. 39:4 (2011), 716–744 http://doi.org/10.1177/0192623311406935.
61. Smith, M.T., Guyton, K.Z., Gibbons, C.F., Fritz, J.M., Portier, C.J., Rusyn, I., Straif, K., Key characteristics of carcinogens as a basis for organizing data on mechanisms of carcinogenesis. Environ. Health Perspect., 2016, 10.1289/ehp.1509912.
62. Straif, Kurt, Loomis, D., Guyton, K., Grosse, Y., Lauby-Secretan, B., El Ghissassi, F., Bouvard, V., Benbrahim-Tallaa, L., Guha, N.M., Future priorities for the IARC monographs. Lancet Oncol. 15:7 (2014), 683–684.
63. Thayer, K.A., Heindel, J.J., Bucher, J.R., Gallo, M.A., Role of environmental chemicals in diabetes and obesity: a national toxicology program workshop review. Environ. Health Perspect., 2012, 10.1289/ehp.1104597.
64. Tice, R.R., Austin, C.P., Kavlock, R.J., Bucher, J.R., Improving the human hazard characterization of chemicals: a Tox21 update. Environ. Health Perspect., 2013, 10.1289/ehp.1205784.
65. Tomatis, L., Aitio, A., Wilbourn, J., Shuker, L., Human carcinogens so far identified. Jpn. J. Cancer Res. 80:9 (1989), 795–807 http://doi.org/10.1111/j.1349-7006.1989.tb01717.x.
66. Vaccari, M., Mascolo, M.G., Rotondo, F., Morandi, E., Quercioli, D., Perdichizzi, S., Colacci, A., Identification of pathway-based toxicity in the BALB/c 3T3 cell model. Toxicol. in Vitro 29:6 (2015), 1240–1253 http://doi.org/10.1016/j.tiv.2014.10.002.
67. Van Oosterhout, J.P., Van der Laan, J.W., De Waal, E.J., Olejniczak, K., Hilgenfeld, M., Schmidt, V., Bass, R., The utility of two rodent species in carcinogenic risk assessment of pharmaceuticals in Europe. Regul. Toxicol. Pharmacol. 25:1 (1997), 6–17 http://doi.org/10.1006/rtph.1996.1077.
68. VICH GL28, Studies to evaluate the safety of residues of veterinary drugs in human food: carcinogenicity testing. Guidance for Industry, Revision(Step 9), 2005, 1–5.
69. Vinken, M., Doktorova, T., Ellinger-Ziegelbauer, H., Ahr, H.-J., Lock, E., Carmichael, P., Rogiers, V., The carcinoGENOMICS project: critical selection of model compounds for the development of omics-based in vitro carcinogenicity screening assays. Mutat. Res. Rev. Mutat. Res. 659:3 (2008), 202–210 http://doi.org/10.1016/j.mrrev.2008.04.006.
70. Wilbourn, J., Haroun, L., Heseltine, E., Kaldor, J., Partensky, C., Vainio, H., Response of experimental animals to human carcinogens: an analysis based upon the iarc monographs programme. Carcinogenesis 7:11 (1986), 1853–1863 http://doi.org/10.1093/carcin/7.11.1853.